FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand
Executive Summary
Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.
You may also be interested in...
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.
FDA Will Allow ANDA Corrections … Until 10 Minor Deficiencies Found
GDUFA refuse-to-receive draft guidance says that agency will allow sponsors to make a few small fixes to their applications, but FDA won’t accept any ANDAs that have big problems.